Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide expression profile of human melanoma patient derived xenograft (PDX) tumors that were treated with ARN22089 at 0 (vehicle), 10 mg/kg and 25 mg/kg IV in NSG mice (NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ)

ABSTRACT: Genome-wide expression profile of human melanoma patient derived xenograft (PDX) tumors that were treated with ARN22089 at 0 (vehicle), 10 mg/kg and 25 mg/kg IV in NSG mice (NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ)

PROVIDER: PRJNA808757 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18082479_1.fastq.gz	Fastqsanger.gz
	SRR18082479_2.fastq.gz	Fastqsanger.gz
	SRR18082480_1.fastq.gz	Fastqsanger.gz
	SRR18082480_2.fastq.gz	Fastqsanger.gz
	SRR18082481_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

NSG-adapted reference genome - TRACERx PDX study

Project description:NSG-adapted reference genome - TRACERx PDX study

| PRJEB65917 | ENA

Preclinical study with a CD40 agonist on patient-derived xenograft mice for the treatment of B-cell acute lymphoblastic leukemia

Project description:To induce leukemia in NOD/SCID/γc−/− (NSG) mice, we injected 10^5 human B-ALL cells, into the tail vein of non-irradiated mice. Two different PDX mice models were studied (PDX-1; #1 and PDX-2; #2). The InVivoMAb anti-human CD40 antibody (BE0189, clone G28.5, BioXCell) was i.v. administrated (CD40) at the dose of 1 mg/kg, the same was done with the recommended isotype (Ig) (BE0083, MOPC-21, BioXCell). We administrated antibodies, at days 15 and 25. At day 35, when mice developed leukemia, B-ALL cells were purified from the BM of PDX-mice, with magnetic beads-conjugated to human CD45 antibodies. Three mice per condition were tested (replicat 1 to 3; mice m1 to m3).

2024-10-10 | PXD047749 | Pride

80 mg/kg mixed MCBA dosing (10 mg/kg indiv.) via PBFM

Project description:Mixed MCBA PBFM dosing of wild-type C57BL/6Crl mice. 80 mg/kg total bile acid dose (10 mg/kg individual MCBA). MCBAs included in the dosing included AlaCA, AspCA, GluCA, LeuCA, PheCA, SerCA, ThrCA, and TyrCA.

2023-10-21 | MSV000093171 | MassIVE

Transcription profiling of total of rat liver samples treated with 300 mg/kg/day myclobutanil, 300 mg/kg/day propiconazole, and 175 mg/kg/day triadimefon

Project description:The modes of triazole reproductive toxicity have been characterized by an observed increased in serum testosterone and reduced insemination and fertility indices. The key events involved in the disruption in testosterone homeostasis and reduced fertility remain unclear. Gene expression analysis was conducted on liver from Sprague Dawley rats dosed with myclobutanil (300 mg/kg/day), propiconazole (300 mg/kg/day), or triadimefon (175 mg/kg/day) for 72 hours. Pathway-based analysis highlighted key biological processes affected by all three triazoles in the liver including fatty acid catabolism, steroid metabolism, and xenobiotic metabolism. Within the pathways identified in the liver, specific genes involved in phase I-III metabolism and fatty acid metabolism were affected by all three triazoles. These modulated genes are part of a network of lipid and testosterone homeostasis pathways regulated by the constitutive androstane (CAR) and pregnane X (PXR) receptors. Gene expression profiles from this study indicate triazoles activate CAR and PXR; increase fatty acid catabolism and steroid metabolism in the liver; constituting a plausible series of key events contributing to the observed disruption in testosterone homeostasis. Experiment Overall Design: A total of 12 liver samples were analyzed. Three biological replicates each for the controls, 300 mg/kg/day myclobutanil, 300 mg/kg/day propiconazole, and 175 mg/kg/day triadimefon.

2008-04-08 | E-GEOD-10409 | biostudies-arrayexpress

ATAC-seq for LuCaP145.2 tumors treated with 50 mg/kg JQ1 or 10 mg/kg AZD5153 for 7 days

Project description:ATAC-seq for LuCaP145.2 tumors treated with 50 mg/kg JQ1 or 10 mg/kg AZD5153 for 7 days

| PRJNA1104154 | ENA

Genome-wide expression profile of human melanoma patient derived xenograft (PDX) tumors that were treated with ARN22089 at 0 (vehicle), 10 mg/kg and 25 mg/kg IV in NSG mice (NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ)

Project description:To determine the long-term ARN22089 treatment on tumor growth

2022-02-23 | GSE197068 | GEO

5.0 mg/kg MeHg exposure

Project description:In this time course pregnant CD-1 (outbred) dams were exposed to MeHg as monomethylmercuric chloride intraperitoneally on 9 d.p.c. The test dose of 5.0 mg/kg MeHg was selected as a dose with an estimated 20% increased risk for encephalopathy in term fetuses, with no evidence of maternal toxicosis. Sampling intervals ranged from 1.5h to 24.0h post-exposure. All measurements were on RNA from the embryonic forebrain (prosencephalon) using contemporous control embryos as a reference. Keywords = time series Keywords = mercury Keywords = embryo Keywords = Fetal Minamata Disease Keywords: time-course

2004-03-11 | GSE1076 | GEO

100 mg kg serocholate dosing via PBFM

Project description:Data from 100 mg/kg SerCA dosing via PBFM (peanut butter feeding method).

2023-10-20 | MSV000093169 | MassIVE

2.5 mg/kg 2CdA exposure

Project description:In this time course pregnant CD-1 (outbred) dams were exposed to the 2-chloro analogue of 2'-deoxyadenosine (a metabolic toxin) on 8 d.p.c. The test dose of 2.5 mg/kg 2CdA was modeled for a 5% increased risk of microphthalmia in term fetuses. Sampling intervals were anchored to the conditional biomarker (p53 protein induction) expressed in 2CdA-treated embryos between 3.0- and 4.5h post-exposure. Since p53 protein induction has been defined as a critical event in 2CdA-induced micropthalmia, these sampling intervals represent times before (3.0h), during (4.5h), and after (6.0h) this critical event. All measurements were on RNA from the embryonic headfold. Keywords = time series Keywords = 2-chloro-2'-deoxyadenosine Keywords = embryo Keywords = p53 protein induction Keywords = microphthalmia Keywords: time-course

2004-03-11 | GSE1069 | GEO

10 mg/kg PheCA, SerCA dosing via PBFM

Project description:Data from 10 mg/kg MCBA dosing via peanut butter feeding method.

2023-10-20 | MSV000093170 | MassIVE